Previous 10 | Next 10 |
Noteworthy events during the week of March 17 - 23 for healthcare investors. More news on: SCYNEXIS, Inc., Sage Therapeutics, Inc., Intrexon Corporation, Healthcare stocks news, , Read more ...
Lexicon Pharmaceuticals ( LXRX ) has long been a volatile stock, even by the standards of biotech, and whether it can move out of its current doldrums has everything to do with next week’s FDA decision on Zynquista for Type 1 diabetes (or T1D). With Xermelo relegated to an “is ...
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2018 Earnings Conference Call March 13, 2019, 08:00 ET Company Participants Kimberly Lee - Head, Investor Relations and Corporate Strategy Lonnel Coats - President, CEO & Director Alexander Santini - EVP & Chief Commercial Officer ...
Lexicon Pharmaceuticals ( LXRX ) Q4 results : Revenues: $17.1M (-49.7%); Net product revenue: $7.5M (38.9%); Collaborative agreements: $9.5M (-66.5%); Royalties and other revenue: $0.07M (-30.0%). More news on: Lexicon Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and comme...
Lexicon Pharmaceuticals (NASDAQ: LXRX ): Q4 GAAP EPS of -$0.16 beats by $0.12 . More news on: Lexicon Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
XERMELO ® (telotristat ethyl) 2018 U.S. Net Sales Reached $25.0 Million Sotagliflozin in Type 1 Diabetes: March 22 PDUFA Date in U.S., European Commission Decision Expected in Q2 2019 Following Recently-Received Positive CHMP Opinion THE WOODLANDS, Texas, March 13, 2019 (GL...
THE WOODLANDS, Texas, March 11, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter and full-year 2018 financial results on Wednesday, March 13, 2019 before market opens. Management will conduct a conference call and live webcast at 8:0...
SAN DIEGO, March 05, 2019 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX). Investors, who purchased shares of Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX), have certain...
Gainers: Bio-Path Holdings (NASDAQ: BPTH ) +130% . Puma Biotechnology (NYSE: PBYI ) +42% . Lexicon Pharmaceuticals (NASDAQ: LXRX ) +30% . GlobalSCAPE (NYSEMKT: GSB ) +29% . Castlight Health (NYSE: CSLT ) +24% . Farfetch Limited (NYSE: FTCH ) +23% . Sequential Brands Group (NASD...
Puma Biotechnology (NYSE: PBYI ) +30% on Q4 earnings . More news on: Puma Biotechnology, Inc., Funko, Inc., The Gap, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
INPEFA ® (sotagliflozin) Net Sales of $1.6 Million in Q2 2024 Resubmitted NDA for ZYNQUISTA ™ (sotagliflozin) in Type 1 Diabetes, Launch Preparations Underway with PDUFA Goal Date of December 20, 2024 Commenced SONATA Phase 3 Study...
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...